Form 4: ADC Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO of ADC Therapeutics, Ameet Mallik, sold shares to cover tax withholding obligations related to vesting and settlement of restricted share units.
Summary
- On May 7, 2024, Ameet Mallik, the CEO of ADC Therapeutics SA, sold 29,731 common shares at a price of $4.48 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of restricted share units.
- Following the transaction, Mallik still beneficially owns 1,167,348 common shares.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (selling shares to cover taxes on vested equity). It's neither particularly positive nor negative.
Industry Context
Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation like restricted stock units.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholders, potentially causing a slight decrease in share price due to increased supply, but this is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 05/07/2024 | Date of the transaction: sale of common shares. |
| 05/09/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.